xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma

被引:0
作者
Nissi, Linda [1 ,2 ,3 ]
Tuominen, Sanni [4 ,5 ]
Routila, Johannes [3 ,6 ]
Huusko, Teemu [3 ,6 ]
Ketonen, Petra [4 ,5 ]
Sundvall, Maria [1 ,2 ,3 ,7 ]
Leivo, Ilmo [3 ,8 ]
Irjala, Heikki [3 ,6 ]
Minn, Heikki [1 ,2 ,3 ]
Gronroos, Tove J. [1 ,4 ,5 ]
Ventela, Sami [6 ,9 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, FICAN West Canc Ctr, Turku, Finland
[3] Univ Turku, Turku, Finland
[4] Univ Turku, Preclin Imaging Turku PET Ctr, Turku, Finland
[5] Univ Turku, Med Res Lab, Turku, Finland
[6] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland
[7] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland
[8] Turku Univ Hosp, Dept Pathol, Turku, Finland
[9] Univ Turku, Turku Biosci Ctr, Turku, Finland
关键词
CYSTEINE/GLUTAMATE TRANSPORTER; CISPLATIN RESISTANCE; CANCER-CELLS; FOLLOW-UP; FERROPTOSIS; BIOMARKER; SLC7A11; SULFASALAZINE; SUPPRESSION; RECURRENCE;
D O I
10.1002/cam4.70371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population-based dataset, comprising all patients (n = 1033) diagnosed with new HNSCC during 2005-2015 in a population of 697,000 people. All patients (n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow-up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti-xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5-year overall survival (OAS) (HR: 2.71; 95% CI 1.67-4.39; p < 0.001), disease-specific survival (DSS) (HR: 2.58; 95% CI 1.47-4.54; p = 0.001), and disease-free survival (DFS) (HR: 2.69; 95% CI 1.55-4.64; p < 0.001). Five-year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T-class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3-year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
引用
收藏
页数:10
相关论文
共 56 条
[1]   Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring [J].
Beswick, Daniel M. ;
Gooding, William E. ;
Johnson, Jonas T. ;
Branstetter, Barton F. .
LARYNGOSCOPE, 2012, 122 (07) :1512-1517
[2]   THE VALUE OF FOLLOW-UP IN PATIENTS TREATED FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BOYSEN, M ;
LOVDAL, O ;
TAUSJO, J ;
WINTHER, F .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :426-430
[3]   Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma [J].
Chera, Bhishamjit S. ;
Amdur, Robert J. .
SEMINARS IN RADIATION ONCOLOGY, 2018, 28 (01) :27-34
[4]   Head and Neck Cancer [J].
Chow, Laura Q. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :60-72
[5]   Exposure to alcohol and overall survival in head and neck cancer: A regional cohort study [J].
Denissoff, Alexander ;
Huusko, Teemu ;
Ventela, Sami ;
Niemela, Solja ;
Routila, Johannes .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (10) :2109-2117
[6]   Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death [J].
Dixon, Scott J. ;
Lemberg, Kathryn M. ;
Lamprecht, Michael R. ;
Skouta, Rachid ;
Zaitsev, Eleina M. ;
Gleason, Caroline E. ;
Patel, Darpan N. ;
Bauer, Andras J. ;
Cantley, Alexandra M. ;
Yang, Wan Seok ;
Morrison, Barclay, III ;
Stockwell, Brent R. .
CELL, 2012, 149 (05) :1060-1072
[7]   Recurrent carcinoma of the head and neck: treatment strategies and survival analysis in a 20-year period [J].
Eckardt, A ;
Barth, EL ;
Kokemueller, H ;
Wegener, G .
ORAL ONCOLOGY, 2004, 40 (04) :427-432
[8]  
Feng H., 2022, Oxidative Medicine and Cellular Longevity, P1
[9]   Unsolved mysteries: How does lipid peroxidation cause ferroptosis? [J].
Feng, Huizhong ;
Stockwell, Brent R. .
PLOS BIOLOGY, 2018, 16 (05)
[10]   Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial [J].
Gillison, Maura L. ;
Trotti, Andy M. ;
Harris, Jonathan ;
Eisbruch, Avraham ;
Harari, Paul M. ;
Adelstein, David J. ;
Sturgis, Erich M. ;
Burtness, Barbara ;
Ridge, John A. ;
Ringash, Jolie ;
Galvin, James ;
Yao, Min ;
Koyfman, Shlomo A. ;
Blakaj, Dukagjin M. ;
Razaq, Mohammed A. ;
Colevas, A. Dimitrios ;
Beitler, Jonathan J. ;
Jones, Christopher U. ;
Dunlap, Neal E. ;
Seaward, Samantha A. ;
Spencer, Sharon ;
Galloway, Thomas J. ;
Phan, Jack ;
Dignam, James J. ;
Quynh Thu Le .
LANCET, 2019, 393 (10166) :40-50